---
title: "Novo Nordisk completely dismantles the diabetes cell therapy department"
description: "Danish pharmaceutical company Novo Nordisk announced on Friday the closure of its cell therapy department, which is responsible for drug development for Type 1 diabetes. The company stated in a statem"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260680169.md"
published_at: "2025-10-10T18:33:29.000Z"
---

# Novo Nordisk completely dismantles the diabetes cell therapy department

> Danish pharmaceutical company Novo Nordisk announced on Friday the closure of its cell therapy department, which is responsible for drug development for Type 1 diabetes. The company stated in a statement that it is seeking partners to continue advancing related research. According to reports from《Borsen》, nearly all of the approximately 250 employees in that department were laid off, and Novo Nordisk did not disclose further specific details

Danish pharmaceutical company Novo Nordisk (NVO.US) announced on Friday the closure of its cell therapy department, which was responsible for drug development for Type 1 diabetes.

The company stated in a statement that it is seeking partners to continue advancing related research. According to reports from Borsen, nearly all of the approximately 250 employees in that department were laid off, and Novo Nordisk did not disclose further specific details

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/en/news/276442777.md) |
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/en/news/276314777.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/en/news/276447697.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/en/news/276280378.md) |
| Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | [Link](https://longbridge.com/en/news/276440991.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.